Anavex Life Sciences (AVXL) Share-based Compensation Growth (3y) (2013 - 2025)
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Stock Comp. Growth (3y) (Qtr) |
|---|---|---|---|---|---|
| 1 | Quantum Biopharma | 961,148.99 Bn | 961,148.98 Bn | - | -34.72% |
| 2 | Alterity Therapeutics | 744,933.29 Bn | 744,933.26 Bn | - | - |
| 3 | Legend Biotech | 2,540.00 Bn | 2,539.71 Bn | 242.10 Mn | - |
| 4 | Nanobiotix | 2,199.85 Bn | 2,199.78 Bn | - | - |
| 5 | Akari Therapeutics | 1,635.88 Bn | 1,635.88 Bn | - | 4.80% |
| 6 | Vertex Pharmaceuticals | 111.32 Bn | 104.07 Bn | 2.59 Bn | 10.78% |
| 7 | Evaxion A | 62.56 Bn | 62.54 Bn | - | - |
| 8 | Regeneron Pharmaceuticals | 62.55 Bn | 53.79 Bn | 3.31 Bn | 2.55% |
| 9 | Alnylam Pharmaceuticals | 39.57 Bn | 36.56 Bn | 959.66 Mn | 20.65% |
| 10 | Anavex Life Sciences | 266.20 Mn | 134.45 Mn | - | -40.84% |
Historic Data
Download Data| Date | Value |
|---|---|
| Dec 31, 2025 | -40.84% |
| Sep 30, 2025 | 6.14% |
| Jun 30, 2025 | 2.73% |
| Mar 31, 2025 | -31.15% |
| Dec 31, 2024 | -19.29% |
| Sep 30, 2024 | 30.52% |
| Jun 30, 2024 | 47.76% |
| Mar 31, 2024 | 12.83% |
| Dec 31, 2023 | 34.51% |
| Sep 30, 2023 | 69.50% |
| Jun 30, 2023 | 45.65% |
| Mar 31, 2023 | 32.65% |
| Dec 31, 2022 | 61.71% |
| Sep 30, 2022 | 69.89% |
| Jun 30, 2022 | 47.85% |
| Mar 31, 2022 | 32.86% |
| Dec 31, 2021 | 23.66% |
| Sep 30, 2021 | 27.90% |
| Jun 30, 2021 | 10.99% |
| Mar 31, 2021 | 14.63% |
| Dec 31, 2020 | -5.75% |
| Sep 30, 2020 | -16.08% |
| Jun 30, 2020 | 2.56% |
| Mar 31, 2020 | 20.63% |
| Dec 31, 2019 | 12.45% |
| Sep 30, 2019 | -31.13% |
| Jun 30, 2019 | 75.01% |
| Mar 31, 2019 | 104.09% |
| Dec 31, 2018 | 35.76% |
| Sep 30, 2018 | 2.91% |
| Jun 30, 2018 | 429.78% |
| Dec 31, 2017 | 318.00% |
| Sep 30, 2017 | 21.16% |
| Jun 30, 2017 | 394.53% |
| Sep 30, 2016 | 55.72% |
| Jun 30, 2015 | -51.48% |
| Dec 31, 2014 | -50.05% |
| Sep 30, 2014 | 34.59% |
| Jun 30, 2014 | -60.80% |
| Sep 30, 2013 | 90.10% |